CA Patent

CA2929652A1 — Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors

Assigned to Dana Farber Cancer Institute Inc · Expires 2015-05-14 · 11y expired

What this patent protects

The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.

USPTO Abstract

The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.

Drugs covered by this patent

Zykadia (ceritinib) · Novartis

Patent Metadata

Patent number: CA2929652A1
Jurisdiction: CA
Classification: —
Expires: 2015-05-14
Drug substance claim: No
Drug product claim: No
Assignee: Dana Farber Cancer Institute Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.